Turn Therapeutics Inc. (TTRX): who owns it and who trades it
As of Nov 16, 2026, TTRX insiders reported 6 purchases worth $118K in the last 12 months. The largest buyer was Arthur F Golden (Director), with $92.9K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Turn Therapeutics
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, TTRX insiders reported $118K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | Zuraiz Chaudhary | See Remarks | Purchase | 2,500 | $3.50 | $8.8K | Form 4 |
| Nov 24, 2025 | Arthur F Golden | Director | Purchase | 9,868 | $3.44 | $33.9K | Form 4 |
| Nov 21, 2025 | Arthur F Golden | Director | Purchase | 20,532 | $2.87 | $58.9K | Form 4 |
| Nov 21, 2025 | Zuraiz Chaudhary | See Remarks | Purchase | 1,000 | $3.29 | $3.3K | Form 4 |
| Nov 20, 2025 | Zuraiz Chaudhary | See Remarks | Purchase | 1,450 | $2.61 | $3.8K | Form 4 |
| Nov 17, 2025 | Zuraiz Chaudhary | See Remarks | Purchase | 2,500 | $3.62 | $9.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Arthur F Golden | Director | $92.9K | – | Nov 24, 2025 |
| Zuraiz Chaudhary | See Remarks | $24.9K | – | Dec 12, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TTRX short interest
Low short interest. 1.8% of TTRX shares are sold short: about 1 share in 56. Over the last 12 reports the number of shares short went up 721%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 530,526 TTRX shares were sold short, 1.8% of the shares outstanding, up 23.0% from the report before. At the average daily volume of 90,436 shares, buying them all back would take about 5.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 530,526 | 1.78% | +23% | 90,436 | 5.9 |
| Oct 15, 2026 | 431,200 | 1.45% | +60% | 101,360 | 4.2 |
| Sep 30, 2026 | 268,757 | 0.90% | +74% | 201,829 | 1.3 |
| Sep 15, 2026 | 154,372 | 0.52% | +16% | 135,386 | 1.1 |
| Aug 31, 2026 | 132,779 | 0.45% | +16% | 41,383 | 3.2 |
| Aug 14, 2026 | 114,828 | 0.39% | +36% | 58,949 | 1.9 |
| Jul 31, 2026 | 84,329 | 0.28% | +46% | 90,456 | 1.0 |
| Jul 15, 2026 | 57,729 | 0.19% | +50% | 167,824 | 1.0 |
| Jun 30, 2026 | 38,506 | 0.13% | +25% | 41,675 | 1.0 |
| Jun 15, 2026 | 30,684 | 0.10% | -52% | 72,651 | 1.0 |
| May 29, 2026 | 63,729 | 0.21% | -1% | 65,133 | 1.0 |
| May 15, 2026 | 64,613 | 0.22% | +26% | 22,950 | 2.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Turn Therapeutics company events
Turn Therapeutics filed 22 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026AnnouncementShared information with investors. Filing
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 7, 2026AnnouncementShared information with investors. Filing
- Sep 10, 2026AnnouncementShared information with investors. Filing
- Sep 9, 2026AnnouncementShared information with investors. Filing
- Aug 18, 2026SharesSold new shares outside a public offering. Filing
- Aug 17, 2026AnnouncementShared information with investors. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jul 28, 2026AnnouncementShared information with investors. Filing
- Jul 7, 2026AnnouncementShared information with investors. Filing
- Jun 3, 2026AnnouncementShared information with investors. Filing
- Jun 1, 2026AnnouncementShared information with investors. Filing
- May 27, 2026AnnouncementShared information with investors. Filing
- May 19, 2026AnnouncementShared information with investors. Filing
- May 18, 2026AnnouncementShared information with investors. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Mar 31, 2026ResultsReleased financial results. Filing
- Mar 24, 2026AgreementTurn Therapeutics Inc. entered into a Loan and Security Agreement and a Supplement to the Loan and Security Agreement (the “Supplement” and, together with the Loan and Security Agreement, the “Loan Agreement”), with Avenue Venture Opportunities Fund II, L.P., as administrative agent, collateral… Filing
- Feb 17, 2026AnnouncementShared information with investors. Filing
- Feb 9, 2026AnnouncementShared information with investors. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Jan 7, 2026LeadershipThe board of directors of Turn Therapeutics Inc. enlarged the Board from five to six members and appointed Martin Dewhurst to the Board, effective immediately. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Turn Therapeutics financials
Famous investors that hold TTRX
1 of the 50 well-known investors we track reported holding TTRX in their latest 13F filing. The largest position is Israel Englander's, worth $2.4M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 167,802 | $2.4M | 0.0% | +177% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Turn Therapeutics Inc. (TTRX) stock
Are TTRX insiders buying or selling?
In the last 12 months, TTRX insiders reported 6 open-market purchases worth $118K and no sales. The latest trade was on Dec 12, 2025. See every trade.
What is the short interest in TTRX?
As of Oct 30, 2026, 530,526 TTRX shares were sold short, 1.8% of the shares outstanding, up 23.0% from the report before. At the average daily volume of 90,436 shares, buying them all back would take about 5.9 trading days (days to cover). See the history.
Which famous investors hold TTRX?
1 of the 50 well-known investors we track reported TTRX in their latest 13F filing, including Israel Englander. The largest position is worth $2.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.